Generic Name and Formulations:
Amoxicillin, clavulanic acid (as potassium); 250mg/125mg, 500mg/125mg, 875mg/125mg; tabs.
Dr. Reddy's Laboratories, Inc.
Indications for AUGMENTIN:
Susceptible infections including community-acquired pneumonia and acute bacterial sinusitis (see full labeling).
Take with meals. Base dose on amoxicillin component. Due to clavulanic acid component: two 250mg tabs are not equivalent to one 500mg tab; also, the 250mg tab and the 250mg chewable tab are not interchangeable. May use 125mg/5mL or 250mg/5mL susp in place of 500mg tab; or 200mg/5mL or 400mg/5mL susp in place of 875mg tab. Severe infections or respiratory tract infections: 875mg every 12 hrs or 500mg every 8 hrs. Others: 500mg every 12 hrs or 250mg every 8 hrs. Renal impairment: CrCl<30mL/min: do not use 875mg tabs. CrCl: 10–30mL/min: 250–500mg every 12 hrs. CrCl<10mL/min: 250mg–500mg every 24 hrs; hemodialysis: give additional doses during and after dialysis.
Take with meals. Base dose on amoxicillin component. <12 weeks: 30mg/kg/day in 2 divided doses every 12 hrs (use 125mg/5mL). ≥12 weeks: Twice-daily regimen: use 200mg/5mL or 400mg/5mL. Three times daily regimen: use 125mg/5mL or 250mg/5mL. Less severe infections: 25mg/kg/day in 2 divided doses every 12 hrs or 20mg/kg/day in 3 divided doses every 8 hrs. Others: 45mg/kg/day in 2 divided doses every 12 hrs or 40mg/kg/day in 3 divided doses every 8 hrs. ≥40kg: see Adult dose.
History of Augmentin-associated cholestatic jaundice/hepatic dysfunction. XR: Severe renal impairment (CrCl <30mL/min) or hemodialysis.
Cephalosporin, imipenem, or other allergy: not recommended. Monitor blood, renal, and hepatic function in long-term use. Hepatic dysfunction. Mononucleosis. Elderly (consider monitoring renal function). Labor & delivery. Pregnancy (Cat.B). Nursing mothers.
Broad-spectrum penicillin + β-lactamase inhibitor.
May cause false (+) glucose test with Clinitest, Benedict's or Fehling's soln. Probenecid potentiates amoxicillin. May potentiate oral anticoagulants (monitor). May antagonize oral contraceptives.
Diarrhea, nausea, abdominal pain, rash, urticaria, vomiting, vaginitis; anaphylaxis.
XR tabs—28, 40; Tabs 250mg—30; Tabs 500mg, 875mg—20; Susp 125mg/5mL, 250mg/5mL—75mL, 100mL, 150mL; Susp 200mg/5mL, 400mg/5mL—50mL, 75mL, 100mL; Chew tabs 125mg, 250mg—30; Chew tabs 200mg, 400mg—20; Susp ES-600 600mg/5mL—50mL, 75mL, 100mL, 125mL, 150mL, 200mL
Sign Up for Free e-newsletters
- Triplet Regimen Found Most Effective for Relapsed/Refractory Multiple Myeloma
- Integrating Preoperative Oral Care Into Cancer Treatment Plans
- Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?
- American Association for Cancer Research Releases Its 2018 Annual Report
- Pulmonary Toxicity Increased in Pediatric Hodgkin Lymphoma Treated With Brentuximab Vedotin
- Benefit of Chemotherapy for Breast Cancer Observed With Midrange Gene Assay Score
- Antioxidant Interaction With Cancer Therapy
- Young Survivors of Breast Cancer Report Sexual Quality of Life Declines After Treatment
- Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT
- Insurance Status Influences Overall Survival in Follicular Lymphoma
- Skin Cancer Screening: Are They Effective?
- Metronidazole, Vancomycin Recommended for C Difficile in Pediatric Oncology, HSCT
- CDC: HPV Vaccination Rates on the Rise Among Adolescents
- High-Dose vs Standard-Dose Flu Vaccine in Elderly Receiving Chemotherapy
- FDA Grants Approval to Novel Treatment for Hairy Cell Leukemia
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|